CoChat

Understanding the pathogenesis of Alzheimer’s disease: will RNA‐Seq realize the promise of transcriptomics?

Open access
Sutherland, Greg T., Janitz, Michal, Kril, Jillian J. · 2011 · Journal of Neurochemistry
Cited by 68

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

J. Neurochem. (2011) 116, 937–946. The prevalence of Alzheimer’s disease (AD) is increasing rapidly in the western world and is poised to have a significant economic and societal impact. Current treatments do not alter the underlying disease processes meaning new treatments are required if this imminent epidemic is to be averted. The clinical manifestations of AD are secondary to a substantial loss of cortical neurons. To be effective, neuroprotective strategies will need to be implemented prior to this cell loss. However, this requires the discovery of both pre‐clinical markers to identify susceptible patients and the early pathogenic mechanisms to serve as therapeutic targets. Although the biomarkers and pathogenic mechanisms may overlap, it is likely that new approaches are required to identify novel elements of the disease. Transcriptomic analyses, that assume no a priori etiological hypotheses, promise much in elucidating the pathogenesis of complex diseases like AD. Microarrays are the most popular platform for transcriptomic analysis and have been applied across AD models, patient samples and postmortem brain tissue. The results of these studies have been largely discordant which could, to some extent, reflect the limitations of this probe‐hybridization‐based methodology. In comparison, whole transcriptome sequencing (RNA‐Seq) utilizes a highly efficient, next‐generation DNA sequencing method with improved dynamic range and scope of transcript detection. RNA‐Seq is not only highly suited to investigations of the genomically complex human brain tissue but it can potentially overcome technical issues inherent to case–control comparisons of postmortem brain tissue in neurodegenerative diseases. The volume of data generated by this platform looms as the major logistical hurdle and a systematic experimental approach will be required to maximise the detection of pathogenically relevant signals. Nevertheless, RNA‐Seq looks set to deliver a quantum leap forward in our understanding of AD pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2010.07157.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 68

Metadata

Authors
Sutherland, G. T., Janitz, M., & Kril, J. J.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2011-01-19
Volume
116
Issue
6
Pages
937-946
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1484127158
Cited by
68
References
29
FWCI
3.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding the pathogenesis of Alzheimer’s disease: will RNA‐Seq realize the promise of transcriptomics? https://app.cochat.ai/papers/10.1111/j.1471-4159.2010.07157.x
The paper
Sutherland, G. T., Janitz, M., & Kril, J. J. (2011). Understanding the pathogenesis of Alzheimer’s disease: will RNA‐Seq realize the promise of transcriptomics? Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2010.07157.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.